Tesamorelin: DPP-IV-Resistant GHRH Analog Research

What Is Tesamorelin?

Tesamorelin (CAS 218949-48-5) is a synthetic 44-amino acid growth hormone-releasing hormone analog in which the natural GHRH(1-44) sequence is preserved in full, but augmented with a trans-3-hexenoic acid group covalently attached at the N-terminus. This single modification fundamentally changes the pharmacokinetic profile of the molecule while preserving its receptor binding activity.

Native GHRH(1-44) has a plasma half-life measured in minutes, limited primarily by dipeptidyl peptidase IV (DPP-IV) cleavage at the Tyr¹-Ala² bond. This cleavage produces GHRH(3-44), which is pharmacologically inactive and unable to bind the GHRH receptor with meaningful affinity. The trans-3-hexenoic acid N-terminal modification in Tesamorelin physically blocks DPP-IV access to this cleavage site, extending the duration of receptor-active compound in biological systems.

Tesamorelin is available from Lone Star Peptide Co. as a lyophilized powder at 5mg and 10mg sizes, verified at ≥99% purity by HPLC with LC-MS identity confirmation. For researchers studying the full range of GHRH analog pharmacology, comparing Tesamorelin alongside CJC-1295 enables investigation of how different stabilization strategies affect receptor activation kinetics.

The DPP-IV Problem and Tesamorelin's Solution

Dipeptidyl peptidase IV (DPP-IV, also known as CD26) is a ubiquitous serine protease responsible for N-terminal dipeptide cleavage from peptides containing a penultimate proline or alanine residue. GHRH has the sequence His-Ala at positions 1-2: a substrate sequence for DPP-IV, making native GHRH acutely vulnerable to rapid inactivation in plasma and tissue.

Multiple GHRH analog development programs have addressed this limitation through different strategies. CJC-1295 substitutes alanine at position 2 with α-aminoisobutyric acid (Aib), which is not recognized by DPP-IV. Tesamorelin takes a different approach, rather than modifying the internal sequence, it adds a trans-3-hexenoic acid moiety to the N-terminus that provides steric blockade of DPP-IV access without altering the amino acid sequence itself.

The practical consequence for research is that Tesamorelin maintains the complete GHRH(1-44) amino acid sequence, which may produce a receptor interaction profile more closely resembling native GHRH than truncated or internally modified analogs: a potentially significant variable in receptor binding studies where sequence fidelity is a research design consideration.

GHRH Receptor Signaling Cascade

The GHRH receptor (GHRHR) is a class B G-protein-coupled receptor expressed primarily on anterior pituitary somatotroph cells. It couples to Gs, activating adenylyl cyclase and producing cAMP accumulation upon ligand binding. Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream effectors including CREB transcription factor and voltage-gated calcium channels on the somatotroph membrane.

PKA-mediated phosphorylation of CREB drives transcriptional activation of the GH gene (GH1), increasing GH mRNA and subsequent protein synthesis. Simultaneously, PKA-dependent calcium channel activation increases intracellular Ca²⁺, triggering secretory vesicle exocytosis and immediate GH release. The combination of increased synthesis (transcriptional) and immediate release (secretory) produces the characteristic biphasic GH pulse seen in published GHRH analog studies.

Tesamorelin's extended half-life relative to native GHRH shifts the receptor activation profile from acute (minutes) to sustained (hours in animal models), enabling investigation of sustained GHRHR activation and its downstream effects on GH pulsatility, IGF-1 production, and downstream metabolic signaling. This sustained activation profile makes Tesamorelin particularly useful for studies examining chronic GH axis activation rather than acute pulse pharmacology.

Comparison with Other GHRH Analogs

The landscape of GHRH analogs used in research includes native GHRH(1-29), GHRH(1-44), CJC-1295 (without DAC), and Tesamorelin, each with distinct sequence length, stabilization strategy, and half-life profile. Understanding these differences is essential for interpreting published literature and designing experiments that will generate comparable data.

For researchers requiring access to multiple GHRH analogs for comparative study, Tesamorelin and CJC-1295 are available through Lone Star Peptide Co. individually. The CJC-1295/Ipamorelin research overview provides additional context on combining GHRH analogs with GHS-R1a agonists for GH pulse amplitude research.

Laboratory Handling and Reconstitution

Tesamorelin reconstitutes readily in sterile water or PBS. Add solvent gently along the vial wall without vortexing. As a 44-amino acid peptide, Tesamorelin may exhibit concentration-dependent aggregation, prepare working solutions at the target experimental concentration rather than high-concentration stock with subsequent dilution. Verify solution clarity before use; any turbidity may indicate peptide aggregation.

Store lyophilized Tesamorelin at −20°C, protected from light and moisture. Reconstituted solutions are stable at 4°C for up to 7 days. For longer storage, aliquot into single-use volumes at −20°C. Avoid repeated freeze-thaw cycles, which can accelerate aggregation in longer peptides. See our lyophilized peptides guide for reconstitution best practices and our storage mistakes guide for common errors to avoid.

The trans-3-hexenoic acid N-terminal modification is chemically stable under standard peptide storage conditions. Exposure to strong oxidizing agents or prolonged incubation at alkaline pH should be avoided. Standard laboratory handling conditions (neutral to mildly acidic pH, aqueous buffer, 4°C) are appropriate for reconstituted working solutions.

Frequently Asked Questions